Femasys (FEMY) 10-Q 14 Nov 23 2023 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Nov. 13, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Document Transition Report	false
Entity File Number	001-40492
Entity Registrant Name	Femasys Inc.
Entity Central Index Key	0001339005
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3713499
Entity Address, Address Line One	3950 Johns Creek Court
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Suwanee
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30024
City Area Code	770
Local Phone Number	500-3910
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Title of 12(b) Security	Common stock, $0.001 par value
Trading Symbol	FEMY
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		21,649,623

Balance Sheets

Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 8,692,435	$ 12,961,936
Accounts receivable, net	103,556	77,470
Inventory, net	602,668	436,723
Other current assets	826,373	655,362
Total current assets	10,225,032	14,131,491
Property and equipment, at cost:
Leasehold improvements	1,195,637	1,195,637
Office equipment	99,344	99,344
Furniture and fixtures	419,303	419,303
Machinery and equipment	2,645,609	2,572,243
Construction in progress	394,957	413,843
Property and equipment, gross	4,754,850	4,700,370
Less accumulated depreciation	(3,594,300)	(3,217,319)
Net property and equipment	1,160,550	1,483,051
Long-term assets:
Lease right-of-use assets, net	2,530,571	319,557
Intangible assets, net of accumulated amortization	388	3,294
Other long-term assets	936,996	958,177
Total long-term assets	3,467,955	1,281,028
Total assets	14,853,537	16,895,570
Current liabilities:
Accounts payable	851,877	510,758
Accrued expenses	569,442	456,714
Note payable	283,334	141,298
Clinical holdback - current portion	72,075	45,206
Lease liabilities - current portion	410,219	373,833
Total current liabilities	2,186,947	1,527,809
Long-term liabilities:
Clinical holdback - long-term portion	54,019	96,658
Lease liabilities - long-term portion	2,168,969	28,584
Total long-term liabilities	2,222,988	125,242
Total liabilities	4,409,935	1,653,051
Commitments and contingencies
Stockholders' equity:
Common stock, $.001 par, 200,000,000 authorized, 16,110,092 shares issued and 15,992,869 outstanding as of September 30, 2023; and 11,986,927 shares issued and 11,869,704 outstanding as of December 31, 2022	16,110	11,987
Treasury stock, 117,223 shares	(60,000)	(60,000)
Warrants	1,581,608	567,972
Additional paid-in-capital	112,877,059	108,857,065
Accumulated deficit	(103,971,175)	(94,134,505)
Total stockholders' equity	10,443,602	15,242,519
Total liabilities and stockholders' equity	$ 14,853,537	$ 16,895,570

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Stockholders' equity:
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	200,000,000	200,000,000
Common stock, issued (in shares)	16,110,092	11,986,927
Common stock, outstanding (in shares)	15,992,869	11,869,704
Treasury stock, shares (in shares)	117,223	117,223

Statements of Comprehensive Los

Statements of Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statements of Comprehensive Loss [Abstract]
Sales	$ 244,361	$ 347,456	$ 858,859	$ 971,974
Cost of sales	86,186	131,451	301,775	356,479
Gross margin	158,175	216,005	557,084	615,495
Operating expenses:
Research and development	2,072,830	1,648,160	5,137,441	4,542,147
Sales and marketing	70,883	90,374	444,678	222,414
General and administrative	1,970,408	1,395,063	4,642,182	4,024,356
Depreciation and amortization	125,318	139,597	391,683	426,480
Total operating expenses	4,239,439	3,273,194	10,615,984	9,215,397
Loss from operations	(4,081,264)	(3,057,189)	(10,058,900)	(8,599,902)
Other income (expense):
Interest income	92,392	80,373	232,133	109,572
Interest expense	(8,033)	(6,005)	(9,903)	(9,622)
Other expense	0	(22)	0	(22)
Other income (expense), net	84,359	74,346	222,230	99,928
Net loss	(3,996,905)	(2,982,843)	(9,836,670)	(8,499,974)
Net loss attributable to common stockholders, basic	(3,996,905)	(2,982,843)	(9,836,670)	(8,499,974)
Net loss attributable to common stockholders, diluted	$ (3,996,905)	$ (2,982,843)	$ (9,836,670)	$ (8,499,974)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.26)	$ (0.25)	$ (0.74)	$ (0.72)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.26)	$ (0.25)	$ (0.74)	$ (0.72)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)	15,093,147	11,813,610	13,369,462	11,810,289
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	15,093,147	11,813,610	13,369,462	11,810,289

Statements of Stockholders' Equ

Statements of Stockholders' Equity - USD ($)	Common Stock [Member]	Treasury Stock [Member]	Warrants [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2021	$ 11,921	$ (60,000)	$ 702,492	$ 108,418,304	$ (82,740,335)	$ 26,332,382
Balance (in shares) at Dec. 31, 2021	11,921,388
Treasury stock, shares (in shares) at Dec. 31, 2021		117,223
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Expiration of Warrant			(134,520)	134,520		0
Issuance of common stock for cash upon exercise of options	$ 10	$ 0	0	16,141	0	16,151
Issuance of common stock for cash upon exercise of options (in shares)	9,445	0
Share-based compensation expense	$ 0	$ 0	0	158,288	0	158,288
Net loss	0	$ 0	0	0	(8,499,974)	(8,499,974)
Treasury stock, shares (in shares) at Sep. 30, 2022		117,223
Balance at Sep. 30, 2022	$ 11,931	$ (60,000)	567,972	108,727,253	(91,240,309)	18,006,847
Balance (in shares) at Sep. 30, 2022	11,930,833
Balance at Jun. 30, 2022	$ 11,931	$ (60,000)	567,972	108,675,491	(88,257,466)	20,937,928
Balance (in shares) at Jun. 30, 2022	11,930,833
Treasury stock, shares (in shares) at Jun. 30, 2022		117,223
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	$ 0	$ 0	0	51,762	0	51,762
Net loss	0	$ 0	0	0	(2,982,843)	(2,982,843)
Treasury stock, shares (in shares) at Sep. 30, 2022		117,223
Balance at Sep. 30, 2022	$ 11,931	$ (60,000)	567,972	108,727,253	(91,240,309)	18,006,847
Balance (in shares) at Sep. 30, 2022	11,930,833
Balance at Dec. 31, 2022	$ 11,987	$ (60,000)	567,972	108,857,065	(94,134,505)	$ 15,242,519
Balance (in shares) at Dec. 31, 2022	11,986,927					11,986,927
Treasury stock, shares (in shares) at Dec. 31, 2022		117,223				117,223
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock and warrants in connection with April 2023 Financing, net of issuance costs	$ 1,318	$ 0	2,526,664	818,014	0	$ 3,345,996
Issuance of common stock and warrants in connection with April 2023 Financing, net of issuance costs (in shares)	1,318,000	0
Issuance of common stock in connection with at-the-market offering, net of issuance costs	$ 3	$ 0	0	3,365	0	3,368
Issuance of common stock in connection with at-the-market offering, net of issuance costs (in shares)	2,869	0
Issuance of common stock in connection with ESPP	$ 3	$ 0	0	1,694	0	1,697
Issuance of common stock in connection with ESPP (in shares)	3,858	0
Exercise of pre-funded warrants	$ 1,879	$ 0	(1,176,533)	1,174,842	0	188
Exercise of pre-funded warrants (in shares)	1,878,722	0
Exercise of common warrants	$ 920	$ 0	(336,495)	1,395,550	0	1,059,975
Exercise of common warrants (in Shares)	919,716
Share-based compensation expense	$ 0	0	0	626,529	0	626,529
Net loss	0	$ 0	0	0	(9,836,670)	$ (9,836,670)
Treasury stock, shares (in shares) at Sep. 30, 2023		117,223				117,223
Balance at Sep. 30, 2023	$ 16,110	$ (60,000)	1,581,608	112,877,059	(103,971,175)	$ 10,443,602
Balance (in shares) at Sep. 30, 2023	16,110,092					16,110,092
Balance at Jun. 30, 2023	$ 15,190	$ (60,000)	1,918,103	110,977,150	(99,974,270)	$ 12,876,173
Balance (in shares) at Jun. 30, 2023	15,190,376
Treasury stock, shares (in shares) at Jun. 30, 2023		117,223
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of common warrants	$ 920	$ 0	(336,495)	1,395,550	0	1,059,975
Exercise of common warrants (in Shares)	919,716
Share-based compensation expense	$ 0	0	0	504,359	0	504,359
Net loss	0	$ 0	0	0	(3,996,905)	$ (3,996,905)
Treasury stock, shares (in shares) at Sep. 30, 2023		117,223				117,223
Balance at Sep. 30, 2023	$ 16,110	$ (60,000)	$ 1,581,608	$ 112,877,059	$ (103,971,175)	$ 10,443,602
Balance (in shares) at Sep. 30, 2023	16,110,092					16,110,092

Statements of Cash Flows

Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss	$ (9,836,670)	$ (8,499,974)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	388,777	407,146
Amortization	2,906	19,334
Amortization of right-of-use assets	274,158	249,972
Inventory reserve	4,972	3,800
Loss on disposal of assets	44,538	0
Share-based compensation expense	626,529	158,288
Changes in operating assets and liabilities:
Accounts receivable	(26,086)	(98,872)
Inventory	(170,917)	(138,666)
Other assets	313,154	359,307
Accounts payable	341,119	(49,449)
Accrued expenses	112,728	45,828
Lease liabilities	(304,004)	(290,104)
Other liabilities	(15,770)	(30,696)
Net cash used in operating activities	(8,244,566)	(7,864,086)
Cash flows from investing activities:
Purchases of property and equipment	(99,018)	(313,598)
Net cash used in investing activities	(99,018)	(313,598)
Cash flows from financing activities:
Proceeds from the issuance of common stock and warrants in April 2023 Financing	3,899,813	0
Equity issuance costs	(547,764)	0
Proceeds from exercise of pre-funded warrants	188	0
Proceeds from exercise of common warrants	1,059,975	0
Proceeds from common stock issued through ESPP and exercised options	1,697	16,151
Net proceeds from issuance of common stock in connection with at-the-market offering	3,373	0
Payments of deferred offering costs	0	(232,845)
Repayment of note payable	(327,006)	(365,926)
Payments under lease obligations	(16,193)	(17,075)
Net cash provided by (used in) financing activities	4,074,083	(599,695)
Net change in cash and cash equivalents	(4,269,501)	(8,777,379)
Cash and cash equivalents:
Beginning of period	12,961,936	24,783,029
End of period	8,692,435	16,005,650
Cash paid for:
Interest	9,903	9,622
Income taxes	4,550	5,050
Non-cash investing and financing activities:
Right-of-use asset obtained in exchange for a lease liability	2,496,968	0
Property and equipment costs included in accounts payable	0	23,037
Commissions and deferred offering costs relating to proceeds from issuance of common stock	6,163	0
Prepaid insurance financed with promissory notes	$ 283,334	$ 280,577

Organization, Nature of Busines

Organization, Nature of Business, and Liquidity	9 Months Ended
	Sep. 30, 2023
Organization, Nature of Business, and Liquidity [Abstract]
Organization, Nature of Business, and Liquidity	(1) Organization, Nature of Business, and Liquidity Organization and Nature of Business Femasys Inc. (the Company or Femasys) was incorporated in Delaware on February 19, 2004 and is headquartered in Suwanee, Georgia. The Company is a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead late-clinical stage product candidate and innovative therapeutic and diagnostic products. The Company currently operates as one segment with an initial focus on servicing the reproductive health needs for those seeking permanent birth control or solutions for infertility Femasys has an expansive intellectual property portfolio which covers both design and utility patents in the U.S. and significant ex-U.S. markets for each product initiative. Femasys has taken concepts internally conceived and protected through development, including domestic and foreign regulatory approvals, and production, through in-house manufacturing. FemBloc® (FemBloc), the Company’s solution for permanent birth control, is based on the Company’s non-surgical platform technology. In June 2023 the Company received approval of its Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) for the pivotal clinical trial of FemBloc. In July 2023 the Company announced the notice of allowance for a new U.S. patent application covering use of FemBloc for female permanent birth control. In August 2023 the Company announced the initiation of enrollment for the pivotal clinical trial of FemBloc. FemaSeed® (FemaSeed), a solution which enables intratubal artificial insemination to provide a lower cost option to in vitro fertilization methods, received approval in April 2021 from the FDA on its IDE and the clinical trial was initiated in July 2021. An updated trial design received approval in October 2022 from the FDA and the trial enrollment is ongoing. In April 2023 the Company received approval to sell FemaSeed in Canada. In September 2023 the Company announced 510(k) clearance from the FDA for FemaSeed for intratubal insemination. FemVue® (FemVue), a solution that enables fallopian tube assessment with ultrasound as an alternative to the radiologic approach (hysterosalpingogram) for the diagnosis of infertility, is approved for sale in the U.S., Japan, and Canada. FemChec® (FemChec) allows for fallopian tube evaluation after a FemBloc procedure to confirm occlusion (or procedure success) and is being studied as part of the FemBloc pivotal trial. FemCath® (FemCath), allows for selective evaluation of an individual fallopian tube as an alternative to the traditional intrauterine catheter that is undirected, is approved for sale in the U.S and Canada. FemCerv® (FemCerv) is an alternative for the diagnosis of cervical cancer by obtaining a comprehensive tissue sample with minimal contamination of the endocervical canal, and is approved for sale in the U.S and Canada. In August 2023 the Company announced it had obtained a Medical Device Establishment License from Health Canada allowing the Company to directly sell its four products, FemaSeed®, FemVue®, FemCath® and FemCerv®, in Canada. Basis of Presentation The Company has prepared the accompanying financial statements pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to these rules and regulations. These financial statements should be read in conjunction with the Company’s audited financial statements and footnotes related thereto for the year ended December 31, 2022 included in our Annual Report on Form 10K filed with the SEC on March 30, 2023 (the Annual Report). There have been no material changes to the Company’s significant accounting policies described in Note 2 to the financial statements included in the Annual Report. In the opinion of management, the unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company’s financial position and the results of its operations and cash flows at the dates for periods presented. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. The most significant estimates used in these financial statements include the valuation of stock options, warrants, useful lives of property and equipment and intangible assets. Estimates for these and other items are subject to change and are reassessed by management in accordance with U.S. GAAP. Actual results could differ from those estimates. Liquidity As of September 30, 2023, the Company had cash and cash equivalents of $8,692,435. The Company plans to finance its operations and development needs with its existing cash and cash equivalents, additional equity and/or debt financing arrangements, and revenue primarily anticipated from the sale of FemVue and FemaSeed to support the Company’s research and development activities, largely in connection with FemBloc. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis, or at all. If the Company is not able to obtain sufficient funds on acceptable terms when needed, the Company’s business, results of operations, and financial condition could be materially adversely impacted. For the nine months ended September 30, 2023, the Company generated a net loss of $9,836,670. The Company expects such losses to increase over the next few years as the Company advances FemBloc through clinical development until FDA approval is received and is available to be marketed in the United States. The Company believes that its cash and cash equivalents as of September 30, 2023 and cash received subsequent to quarter end (see Note 13, Subsequent Events Recently Issued Accounting Pronouncements – Recently Adopted On January 1, 2023, the Company adopted Accounting Standards Update (ASU) 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which the Financial Accounting Standards Board (FASB) issued in June 2016. The new standard changes the accounting for credit losses for financial assets and certain other instruments, including trade receivables and contract assets, which are not measured at fair value through net income. Under legacy standards, we recognize an impairment of receivables when it was probable that a loss had been incurred. Under the new standard, we are required to recognize estimated credit losses expected to occur over the estimated life or remaining contractual life of an asset (which includes losses that may be incurred in future periods) using a broader range of information including reasonable and supportable forecasts about future economic conditions. The guidance is effective for smaller reporting companies as defined by the SEC for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years with early adoption permitted. The Company’s adoption of this new guidance did not have a material impact on the Company’s financial statements and footnote disclosures (unaudited). Recently Issued Accounting Pronouncements – Not Yet Adopted No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s financial statements.

Cash and Cash Equivalents

Cash and Cash Equivalents	9 Months Ended
	Sep. 30, 2023
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	(2) Cash and Cash Equivalents As of September 30, 2023 and December 31, 2022, money market funds included in cash and cash equivalents on the balance sheets were $7,330,371 and $12,553,557, respectively, which represent level 1 within the fair value hierarchy where there are quoted prices in active markets for identical assets.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2023
Inventories [Abstract]
Inventories	(3) Inventories Inventory stated at cost, net of reserve, consisted of the following: September 30, December 31, 2023 2022 Materials $ 361,569 244,498 Work in progress 51,358 100,453 Finished goods 189,741 91,772 Inventory, net $ 602,668 436,723 The FemVue reserve for slow moving, obsolete, or unusable inventories was as of September 30, 2023 and December 31, 2022, respectively.

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2023
Accrued Expenses [Abstract]
Accrued Expenses	(4) Accrued Expenses Accrued expenses consisted of the following: September 30, December 31, 2023 2022 Clinical trial costs $ 313,029 333,440 Compensation costs 155,192 85,191 Franchise taxes — 26,886 Director fees 90,000 — Other 11,221 11,197 Accrued expenses $ 569,442 456,714

Clinical Holdback

Clinical Holdback	9 Months Ended
	Sep. 30, 2023
Clinical Holdback [Abstract]
Clinical Holdback	(5) Clinical Holdback The following table shows the activity within the clinical holdback liability accounts for the nine months ended September 30, 2023: Balance at December 31, 2022 $ 141,864 Clinical holdback retained 4,529 Clinical holdback paid (20,299 ) Balance at September 30 2023 $ 126,094 Less: clinical holdback - current portion (72,075 ) Clinical holdback - long-term portion $ 54,019

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2023
Revenue Recognition [Abstract]
Revenue Recognition	(6) Revenue Recognition Revenue is recognized upon shipment of our goods based upon contractually stated pricing at standard payment terms ranging from 30 to 60 days. All revenue is recognized point in time and no revenue is recognized over time. For the three and nine months ended September 30, 2023 and 2022, there was no revenue recognized from performance obligations satisfied or partially satisfied in prior periods, nor were there any unsatisfied performance obligations as of September 30, 2023 or 2022. The majority of products sold directly to U.S customers are shipped via common carrier, and the customer pays for shipping and handling and assumes control Free on Board (FOB) shipping point. Products shipped to our international distributors are in accordance with their respective agreements; however, the shipping terms are generally EX-Works, reflecting that control is assumed by the distributor at the shipping point. Returns are only accepted with prior authorization from the Company. Items to be returned must be in original unopened cartons and are subject to a 30% restocking fee. Throughout the periods presented, the Company has not had a history of significant returns. The following table summarizes our sales, primarily from FemVue, by geographic region as follows: Three Months Ended September 30, Nine Months Ended September 30, Primary geographical markets 2023 2022 2023 2022 U.S. $ 244,361 289,642 800,814 856,115 International — 57,814 58,045 115,859 Total $ 244,361 347,456 858,859 971,974

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies [Abstract]
Commitments and Contingencies	(7) Commitments and Contingencies Legal Claims Occasionally, the Company may be a party to legal claims or proceedings of which the outcomes are subject to significant uncertainty. In accordance with Accounting Standards Codification Contingencies The Company, as permitted under Delaware law and in accordance with its bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The Company entered into employment agreements with its officers, which provides for indemnification protection in the executive’s capacity as an officer for actions taken within the scope of employment. The maximum amount of potential future indemnification is unlimited; however, the Company has obtained director and officer insurance that limits its exposure. The Company believes the fair value for these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of September 30, 2023 and December 31, 2022.

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2023
Notes Payable [Abstract]
Notes Payable	(8) Notes Payable AFCO Credit Corporation (AFCO) In July 2023, the Company executed a promissory note with AFCO to finance certain insurance premiums totaling $469,042, requiring the Company to pay $48,423 in a down payment and make monthly installment payments. The annual interest rate is 8.587% and the monthly installment is $48,423, which represents principal and interest. As of September 30, 2023 and December 31, 2022, the principal balance on the remaining AFCO promissory notes was $283,334 and $141,298, respectively and is included in Notes payable in the accompanying balance sheets. Interest expense in connection with the AFCO promissory notes was $7,998 and $5,352 for the three months ended September 30, 2023 and 2022, respectively. Interest expense was $9,317 and $7,235 for the nine months ended September 30, 2023 and 2022, respectively .

Leases

Leases	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Leases	(9) Leases Operating Lease April 2029

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2023
Stockholders' Equity [Abstract]
Stockholders' Equity	(10) Stockholders’ Equity In July 2022, the Company entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Piper Sandler & Co. (“Piper Sandler” or the “Sales Agent”) and filed a related Prospectus establishing an “at-the-market” facility, pursuant to which the Company may offer and sell shares of common stock having an aggregate offering price of up to $8,800,000 from time to time through the Sales Agent pursuant to the Prospectus. For the nine months ended September 30, 2023, 2,869 shares of common stock were sold under the Equity Distribution Agreement. In April 2023, the Company suspended its at-the-market facility with the Sales Agent, which was subsequently reinstated in October 2023 (see Note 13, Subsequent Events In April 2023, the Company sold an aggregate of (i) 1,318,000 shares of common stock and (ii) pre-funded warrants to purchase up to 1,878,722 shares of common stock in a registered direct offering (“pre-funded warrants”) and, in a concurrent private placement, warrants to purchase up to 3,196,722 shares of common stock (“common warrants”). Additionally, common warrants were issued to the placement agent to purchase up to 191,803 shares of common stock as compensation for services (“placement agent warrants”), collectively the (“April 2023 Financing”). The purchase price per share for the common stock, pre-funded warrants was $1.22 and $1.2199, respectively. The gross proceeds from the offering were $3,899,813, less placement agent fees and offering expenses of $547,764. The Company intends to use the net proceeds from the offering for general corporate purposes. As of September 30, 2023, the Company had 15,992,869 shares of common stock outstanding, and no dividends have been declared or paid.

Equity Incentive Plans and Warr

Equity Incentive Plans and Warrants	9 Months Ended
	Sep. 30, 2023
Equity Incentive Plans and Warrants [Abstract]
Equity Incentive Plans and Warrants	(11) Equity Incentive Plans and Warrants Stock-Based Awards (a) Stock Option Plans Activity under the Company’s stock option plans for the nine months ended September 30, 2023 was as follows: Number of options Weighted average exercise price Outstanding at December 31, 2022 931,550 $ 3.97 Granted 5,000 1.18 Forfeited (50,055 ) 1.87 Outstanding at March 31, 2023 886,495 $ 4.07 Granted 153,200 0.75 Forfeited (20,024 ) 3.94 Outstanding at June 30, 2023 1,019,671 $ 3.57 Granted 1,064,800 0.49 Forfeited (5,200 ) 1.25 Outstanding at September 30, 2023 2,079,271 $ 2.00 Vested and exercisable at September 30 1,217,298 $ 2.62 Options granted under our 2021 Stock Option Plan for the nine months ended September 30, 2023 to employees and nonemployees were 1,150,000 and 73,000, respectively and the weighted average exercise prices were $0.52 and $0.64, respectively. The weighted-average fair values of the options granted to employees and nonemployees were $0.42 and $0.51, respectively and were estimated using the following Black-Scholes assumptions: Employee Nonemployee Expected term (in years) 5.60 5.49 Risk‑free interest rate 4.06 % 3.96 % Dividend yield — % — % Expected volatility 105.14 % 106.58 % No options were exercised for the nine months ended September 30, 2023 under our stock option plans. As of September 30, 2023, the total number of shares of common stock reserved for future awards under the 2021 Stock Option Plan was 652,314. (b) Inducement Grants For the nine months ended September 30, 2023, no inducement awards were granted. As of September 30, 2023 (c) Share-Based Compensation Expense The following table shows the share-based compensation expense related to vested stock option grants to employees and nonemployees by financial statement line item on the accompanying statement of comprehensive loss: Three Months Ended September 30 Nine September 30 2023 2022 2023 2022 Research and development $ 79,561 10,820 131,812 73,395 Sales and marketing 623 1,515 (1,319 ) 3,857 General and administrative 424,175 39,427 496,036 81,036 Total share-based compensation expense $ 504,359 51,762 626,529 158,288 As September 30, 2023 (d) Employee Stock Purchase Plan (ESPP) For the nine months ended September 30, 2023 September 30, 2023 (e) April 2023 Financing On April 20, 2023, the Company entered into a securities purchase agreement pursuant to which the Company sold (i) 1,318,000 shares of common stock (see Note 10, Stockholders’ Equity The pre-funded warrants, common warrants and placement agent warrants were exercisable immediately following the closing date of the offering. The pre-funded warrants have an unlimited term and an exercise price of $0.0001 per share. The common warrants have a 5.5 year term and an exercise price of $1.095 per share. The placement agent warrants have a 5 year term and exercise price of $1.525 per share. The offering resulted in aggregate gross proceeds of $3,899,813, before $547,764 of transaction costs. The pre-funded warrants and common warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. The common stock was valued at $1,133,480, based on the Company’s stock price. The pre-funded warrants and common warrants were valued at $1,615,701 and $1,854,099, respectively, using the following Black-Scholes assumptions: Pre-funded warrants Common warrants Expected term (in years) 4 4 Risk‑free interest rate 3.83 % 3.83 % Dividend yield — % — % Expected volatility 100.25 % 100.25 % Exercise price $ 0.0001 $ 1.095 Stock price $ 0.86 $ 0.86 Black-Scholes value $ 0.86 $ 0.58 The net proceeds of $3,352,049 were allocated to the common stock, pre-funded warrants and common warrants using the relative fair value method. The valuations were recorded to stockholders’ equity. In June 2023, all pre-funded warrants were exercised for shares of common stock. In September 2023, 796,722 common warrants and 122,994 placement agent warrants were exercised for cash proceeds of $1,059,975

Net Loss per Share Attributable

Net Loss per Share Attributable to Common Stockholders	9 Months Ended
	Sep. 30, 2023
Net Loss per Share Attributable to Common Stockholders [Abstract]
Net Loss per Share Attributable to Common Stockholders	(12) Net Loss per Share Attributable to Common Stockholders The following ta ble sets forth the computation of t Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Net loss attributable to common stockholders, basic & diluted $ (3,996,905 ) (2,982,843 ) (9,836,670 ) (8,499,974 ) Weighted average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted 15,093,147 11,813,610 13,369,462 11,810,289 Net loss per share attributable to common stockholders, basic and diluted $ (0.26 ) (0.25 ) (0.74 ) (0.72 ) The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding because they would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Options to purchase common stock 2,229,271 1,071,573 2,229,271 1,071,573 Warrants to purchase common stock, in connection with April 2023 financing 2,468,809 — 2,468,809 — Warrants to purchase common stock 233,460 233,460 233,460 233,460 Total potential shares 4,931,540 1,305,033 4,931,540 1,305,033

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	(13) Subsequent Events In October 2023, 2,400,000 common warrants were exercised for cash proceeds of $2,628,000. In October 2023, the Company reinstated the at-the-market agreement and authorized the Sales Agent to sell up to $16.7 million shares at current market prices until all shares are sold. In October 2023, the Company sold 3,256,754 shares under this facility, resulting in gross cash proceeds of $7,661,587 .

Organization, Nature of Busin_2

Organization, Nature of Business, and Liquidity (Policies)	9 Months Ended
	Sep. 30, 2023
Organization, Nature of Business, and Liquidity [Abstract]
Organization and Nature of Business	Organization and Nature of Business Femasys Inc. (the Company or Femasys) was incorporated in Delaware on February 19, 2004 and is headquartered in Suwanee, Georgia. The Company is a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead late-clinical stage product candidate and innovative therapeutic and diagnostic products. The Company currently operates as one segment with an initial focus on servicing the reproductive health needs for those seeking permanent birth control or solutions for infertility Femasys has an expansive intellectual property portfolio which covers both design and utility patents in the U.S. and significant ex-U.S. markets for each product initiative. Femasys has taken concepts internally conceived and protected through development, including domestic and foreign regulatory approvals, and production, through in-house manufacturing. FemBloc® (FemBloc), the Company’s solution for permanent birth control, is based on the Company’s non-surgical platform technology. In June 2023 the Company received approval of its Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) for the pivotal clinical trial of FemBloc. In July 2023 the Company announced the notice of allowance for a new U.S. patent application covering use of FemBloc for female permanent birth control. In August 2023 the Company announced the initiation of enrollment for the pivotal clinical trial of FemBloc. FemaSeed® (FemaSeed), a solution which enables intratubal artificial insemination to provide a lower cost option to in vitro fertilization methods, received approval in April 2021 from the FDA on its IDE and the clinical trial was initiated in July 2021. An updated trial design received approval in October 2022 from the FDA and the trial enrollment is ongoing. In April 2023 the Company received approval to sell FemaSeed in Canada. In September 2023 the Company announced 510(k) clearance from the FDA for FemaSeed for intratubal insemination. FemVue® (FemVue), a solution that enables fallopian tube assessment with ultrasound as an alternative to the radiologic approach (hysterosalpingogram) for the diagnosis of infertility, is approved for sale in the U.S., Japan, and Canada. FemChec® (FemChec) allows for fallopian tube evaluation after a FemBloc procedure to confirm occlusion (or procedure success) and is being studied as part of the FemBloc pivotal trial. FemCath® (FemCath), allows for selective evaluation of an individual fallopian tube as an alternative to the traditional intrauterine catheter that is undirected, is approved for sale in the U.S and Canada. FemCerv® (FemCerv) is an alternative for the diagnosis of cervical cancer by obtaining a comprehensive tissue sample with minimal contamination of the endocervical canal, and is approved for sale in the U.S and Canada. In August 2023 the Company announced it had obtained a Medical Device Establishment License from Health Canada allowing the Company to directly sell its four products, FemaSeed®, FemVue®, FemCath® and FemCerv®, in Canada.
Basis of Presentation	Basis of Presentation The Company has prepared the accompanying financial statements pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to these rules and regulations. These financial statements should be read in conjunction with the Company’s audited financial statements and footnotes related thereto for the year ended December 31, 2022 included in our Annual Report on Form 10K filed with the SEC on March 30, 2023 (the Annual Report). There have been no material changes to the Company’s significant accounting policies described in Note 2 to the financial statements included in the Annual Report. In the opinion of management, the unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company’s financial position and the results of its operations and cash flows at the dates for periods presented. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. The most significant estimates used in these financial statements include the valuation of stock options, warrants, useful lives of property and equipment and intangible assets. Estimates for these and other items are subject to change and are reassessed by management in accordance with U.S. GAAP. Actual results could differ from those estimates.
Liquidity	Liquidity As of September 30, 2023, the Company had cash and cash equivalents of $8,692,435. The Company plans to finance its operations and development needs with its existing cash and cash equivalents, additional equity and/or debt financing arrangements, and revenue primarily anticipated from the sale of FemVue and FemaSeed to support the Company’s research and development activities, largely in connection with FemBloc. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis, or at all. If the Company is not able to obtain sufficient funds on acceptable terms when needed, the Company’s business, results of operations, and financial condition could be materially adversely impacted. For the nine months ended September 30, 2023, the Company generated a net loss of $9,836,670. The Company expects such losses to increase over the next few years as the Company advances FemBloc through clinical development until FDA approval is received and is available to be marketed in the United States. The Company believes that its cash and cash equivalents as of September 30, 2023 and cash received subsequent to quarter end (see Note 13, Subsequent Events
Recently Issued Accounting Pronouncements Adopted and Not Yet Adopted	Recently Issued Accounting Pronouncements – Recently Adopted On January 1, 2023, the Company adopted Accounting Standards Update (ASU) 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which the Financial Accounting Standards Board (FASB) issued in June 2016. The new standard changes the accounting for credit losses for financial assets and certain other instruments, including trade receivables and contract assets, which are not measured at fair value through net income. Under legacy standards, we recognize an impairment of receivables when it was probable that a loss had been incurred. Under the new standard, we are required to recognize estimated credit losses expected to occur over the estimated life or remaining contractual life of an asset (which includes losses that may be incurred in future periods) using a broader range of information including reasonable and supportable forecasts about future economic conditions. The guidance is effective for smaller reporting companies as defined by the SEC for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years with early adoption permitted. The Company’s adoption of this new guidance did not have a material impact on the Company’s financial statements and footnote disclosures (unaudited). Recently Issued Accounting Pronouncements – Not Yet Adopted No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s financial statements.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2023
Inventories [Abstract]
Inventory Stated at Cost, Net of Reserve	Inventory stated at cost, net of reserve, consisted of the following: September 30, December 31, 2023 2022 Materials $ 361,569 244,498 Work in progress 51,358 100,453 Finished goods 189,741 91,772 Inventory, net $ 602,668 436,723

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2023
Accrued Expenses [Abstract]
Accrued Expenses	Accrued expenses consisted of the following: September 30, December 31, 2023 2022 Clinical trial costs $ 313,029 333,440 Compensation costs 155,192 85,191 Franchise taxes — 26,886 Director fees 90,000 — Other 11,221 11,197 Accrued expenses $ 569,442 456,714

Clinical Holdback (Tables)

Clinical Holdback (Tables)	9 Months Ended
	Sep. 30, 2023
Clinical Holdback [Abstract]
Clinical Holdback Liability	The following table shows the activity within the clinical holdback liability accounts for the nine months ended September 30, 2023: Balance at December 31, 2022 $ 141,864 Clinical holdback retained 4,529 Clinical holdback paid (20,299 ) Balance at September 30 2023 $ 126,094 Less: clinical holdback - current portion (72,075 ) Clinical holdback - long-term portion $ 54,019

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2023
Revenue Recognition [Abstract]
Sales by Geographic Region	The following table summarizes our sales, primarily from FemVue, by geographic region as follows: Three Months Ended September 30, Nine Months Ended September 30, Primary geographical markets 2023 2022 2023 2022 U.S. $ 244,361 289,642 800,814 856,115 International — 57,814 58,045 115,859 Total $ 244,361 347,456 858,859 971,974

Equity Incentive Plans and Wa_2

Equity Incentive Plans and Warrants (Tables)	9 Months Ended
	Sep. 30, 2023
Equity Incentive Plans and Warrants [Abstract]
Stock Option Plan Activity	Activity under the Company’s stock option plans for the nine months ended September 30, 2023 was as follows: Number of options Weighted average exercise price Outstanding at December 31, 2022 931,550 $ 3.97 Granted 5,000 1.18 Forfeited (50,055 ) 1.87 Outstanding at March 31, 2023 886,495 $ 4.07 Granted 153,200 0.75 Forfeited (20,024 ) 3.94 Outstanding at June 30, 2023 1,019,671 $ 3.57 Granted 1,064,800 0.49 Forfeited (5,200 ) 1.25 Outstanding at September 30, 2023 2,079,271 $ 2.00 Vested and exercisable at September 30 1,217,298 $ 2.62
Estimated Using Assumptions	Options granted under our 2021 Stock Option Plan for the nine months ended September 30, 2023 to employees and nonemployees were 1,150,000 and 73,000, respectively and the weighted average exercise prices were $0.52 and $0.64, respectively. The weighted-average fair values of the options granted to employees and nonemployees were $0.42 and $0.51, respectively and were estimated using the following Black-Scholes assumptions: Employee Nonemployee Expected term (in years) 5.60 5.49 Risk‑free interest rate 4.06 % 3.96 % Dividend yield — % — % Expected volatility 105.14 % 106.58 %
Share-based Compensation Expense	The following table shows the share-based compensation expense related to vested stock option grants to employees and nonemployees by financial statement line item on the accompanying statement of comprehensive loss: Three Months Ended September 30 Nine September 30 2023 2022 2023 2022 Research and development $ 79,561 10,820 131,812 73,395 Sales and marketing 623 1,515 (1,319 ) 3,857 General and administrative 424,175 39,427 496,036 81,036 Total share-based compensation expense $ 504,359 51,762 626,529 158,288
Warrants Valuation Assumptions	The common stock was valued at $1,133,480, based on the Company’s stock price. The pre-funded warrants and common warrants were valued at $1,615,701 and $1,854,099, respectively, using the following Black-Scholes assumptions: Pre-funded warrants Common warrants Expected term (in years) 4 4 Risk‑free interest rate 3.83 % 3.83 % Dividend yield — % — % Expected volatility 100.25 % 100.25 % Exercise price $ 0.0001 $ 1.095 Stock price $ 0.86 $ 0.86 Black-Scholes value $ 0.86 $ 0.58

Net Loss per Share Attributab_2

Net Loss per Share Attributable to Common Stockholders (Tables)	9 Months Ended
	Sep. 30, 2023
Net Loss per Share Attributable to Common Stockholders [Abstract]
Computation of Basic and Diluted Net Loss Per Share	The following ta ble sets forth the computation of t Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Net loss attributable to common stockholders, basic & diluted $ (3,996,905 ) (2,982,843 ) (9,836,670 ) (8,499,974 ) Weighted average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted 15,093,147 11,813,610 13,369,462 11,810,289 Net loss per share attributable to common stockholders, basic and diluted $ (0.26 ) (0.25 ) (0.74 ) (0.72 )
Computations of Diluted Weighted Average Shares Outstanding	The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding because they would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Options to purchase common stock 2,229,271 1,071,573 2,229,271 1,071,573 Warrants to purchase common stock, in connection with April 2023 financing 2,468,809 — 2,468,809 — Warrants to purchase common stock 233,460 233,460 233,460 233,460 Total potential shares 4,931,540 1,305,033 4,931,540 1,305,033

Organization, Nature of Busin_3

Organization, Nature of Business, and Liquidity (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) Segment	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Organization and Nature of Business [Abstract]
Number of operating segments | Segment			1
Liquidity [Abstract]
Cash and cash equivalents	$ 8,692,435		$ 8,692,435		$ 12,961,936
Net loss	$ (3,996,905)	$ (2,982,843)	$ (9,836,670)	$ (8,499,974)

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Level 1 [Member] | Money Market Funds [Member]
Assets, Fair Value Disclosure [Abstract]
Cash and cash equivalent	$ 7,330,371	$ 12,553,557

Inventories (Details)

Inventories (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Inventories [Abstract]
Materials	$ 361,569	$ 244,498
Work in progress	51,358	100,453
Finished goods	189,741	91,772
Inventory, net	602,668	436,723
Reserve for expired inventory	$ 3,560	$ 2,103

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Accrued Expenses [Abstract]
Clinical trail costs	$ 313,029	$ 333,440
Compensation costs	155,192	85,191
Franchise taxes	0	26,886
Director fees	90,000	0
Other	11,221	11,197
Accrued expenses	$ 569,442	$ 456,714

Clinical Holdback (Details)

Clinical Holdback (Details) - USD ($)	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Clinical Holdback Liability [Roll Forward]
Balance	$ 141,864
Clinical holdback retained	4,529
Clinical holdback paid	(20,299)
Balance	126,094
Less: clinical holdback - current portion	(72,075)	$ (45,206)
Clinical holdback - long-term portion	$ 54,019	$ 96,658

Revenue Recognition (Details)

Revenue Recognition (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue Recognition [Abstract]
Revenue recognized from performance obligations in prior periods	$ 0	$ 0	$ 0	$ 0
Percentage of restocking fee			30%
Primary Geographical Markets [Abstract]
Sales	244,361	347,456	$ 858,859	971,974
FemVue [Member]
Primary Geographical Markets [Abstract]
Sales	244,361	347,456	858,859	971,974
FemVue [Member] | U.S. [Member]
Primary Geographical Markets [Abstract]
Sales	244,361	289,642	800,814	856,115
FemVue [Member] | International [Member]
Primary Geographical Markets [Abstract]
Sales	$ 0	$ 57,814	$ 58,045	$ 115,859
Minimum [Member]
Revenue Recognition [Abstract]
Revenue recognition payment period term			30 days
Maximum [Member]
Revenue Recognition [Abstract]
Revenue recognition payment period term			60 days

Notes Payable (Details)

Notes Payable (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Notes Payable [Abstract]
Down payments				$ 327,006	$ 365,926
Note payable		$ 283,334		$ 283,334		$ 141,298
Promissory Notes [Member] | AFCO Credit Corporation [Member]
Notes Payable [Abstract]
Proceeds to pay insurance premiums	$ 469,042
Down payments	$ 48,423
Interest rate	8.587%
Frequency of installment payments				monthly
Monthly principal and interest payments	$ 48,423
Note payable		283,334		$ 283,334		$ 141,298
Interest expense on loan		$ 7,998	$ 5,352	$ 9,317	$ 7,235

Leases (Details)

Leases (Details) - USD ($)	1 Months Ended	9 Months Ended
	Jul. 31, 2023	Sep. 30, 2023	Sep. 30, 2022
Leases [Abstract]
Operating lease payments	$ 3,321,025
Additional operating lease term	63 months
Lease extended date	Apr. 30, 2029
Right-of-use asset obtained in exchange for a lease liability	$ 2,496,968	$ 2,496,968	$ 0

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)		1 Months Ended	9 Months Ended
	Apr. 20, 2023	Apr. 30, 2023	Sep. 30, 2023	Dec. 31, 2022	Jul. 12, 2022
Stockholders Equity [Abstract]
Common stock sold (in shares)	1,318,000
Gross proceeds from offering	$ 3,899,813	$ 3,899,813
Placement agent fees expenses and offering expenses		$ 547,764
Common stock, outstanding (in shares)			15,992,869	11,869,704
Dividends declared or paid			$ 0
Pre-funded Warrants [Member]
Stockholders Equity [Abstract]
Warrants issued to purchase common stock (in shares)	1,878,722
Purchase price (in dollars per share)		$ 1.2199
Pre-funded Warrants [Member] | Maximum [Member]
Stockholders Equity [Abstract]
Warrants issued to purchase common stock (in shares)		1,878,722
Common Warrants [Member]
Stockholders Equity [Abstract]
Warrants issued to purchase common stock (in shares)	3,196,722
Common Warrants [Member] | Maximum [Member]
Stockholders Equity [Abstract]
Warrants issued to purchase common stock (in shares)		3,196,722
Placement Agent Warrants [Member]
Stockholders Equity [Abstract]
Warrants issued to purchase common stock (in shares)	191,803
Placement Agent Warrants [Member] | Maximum [Member]
Stockholders Equity [Abstract]
Warrants issued to purchase common stock (in shares)		191,803
Common Stock [Member]
Stockholders Equity [Abstract]
Authorized offering amount of securities					$ 8,800,000
Common stock sold (in shares)		1,318,000	2,869
Purchase price (in dollars per share)		$ 1.22

Equity Incentive Plans and Wa_3

Equity Incentive Plans and Warrants, Stock Option Plan, Activity (Details) - 2021 Stock Option Plan [Member] - $ / shares	3 Months Ended			9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2023
Number of Options [Roll Forward]
Beginning balance (in shares)	1,019,671	886,495	931,550	931,550
Granted (in shares)	1,064,800	153,200	5,000
Forfeited (in shares)	(5,200)	(20,024)	(50,055)
Ending balance (in shares)	2,079,271	1,019,671	886,495	2,079,271
Weighted Average Exercise Price [Abstract]
Beginning balance (in dollars per share)	$ 3.57	$ 4.07	$ 3.97	$ 3.97
Granted (in dollars per share)	0.49	0.75	1.18
Forfeited (in dollars per share)	1.25	3.94	1.87
Ending balance (in dollars per share)	$ 2	$ 3.57	$ 4.07	$ 2
Options vested and exercisable [Abstract]
Options vested and exercisable, Number of option vested (in shares)	1,217,298			1,217,298
Options vested and exercisable, Exercise price (in dollars per share)	$ 2.62			$ 2.62
Estimated Fair Value Assumptions [Abstract]
Options exercised (in shares)				0
Common stock reserved for issuance (in shares)	652,314			652,314
Employees [Member]
Number of Options [Roll Forward]
Granted (in shares)				1,150,000
Weighted Average Exercise Price [Abstract]
Granted (in dollars per share)				$ 0.52
Options vested and exercisable [Abstract]
Weighted-average fair values of options granted (in dollars per share)				$ 0.42
Estimated Fair Value Assumptions [Abstract]
Expected term (in years)				5 years 7 months 6 days
Risk free interest rate				4.06%
Dividend yield				0%
Expected volatility				105.14%
Nonemployee [Member]
Number of Options [Roll Forward]
Granted (in shares)				73,000
Weighted Average Exercise Price [Abstract]
Granted (in dollars per share)				$ 0.64
Options vested and exercisable [Abstract]
Weighted-average fair values of options granted (in dollars per share)				$ 0.51
Estimated Fair Value Assumptions [Abstract]
Expected term (in years)				5 years 5 months 26 days
Risk free interest rate				3.96%
Dividend yield				0%
Expected volatility				106.58%

Equity Incentive Plans and Wa_4

Equity Incentive Plans and Warrants, Inducement Grant (Details) - Inducement Grant [Member]	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Inducement Grant [Abstract]
Granted (in shares)	0
Shares outstanding (in shares)	150,000
Weighted average exercise price (in dollars per share) | $ / shares	$ 2.42
Options vested and exercisable, Number of option vested (in shares)	25,000
Options vested and exercisable, Weighted average exercise price (in dollars per shares) | $ / shares	$ 2.97

Equity Incentive Plans and Wa_5

Equity Incentive Plans and Warrants, Share-Based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Expense [Abstract]
Share-based compensation expense	$ 504,359	$ 51,762	$ 626,529	$ 158,288
Share-based compensation expense expected to be recognized for employees and nonemployees	864,904		864,904
Compensation expense to be recognized upon achieving certain performance condition			155,222
Unrecognized expenses	709,682		$ 709,682
Weighted-average period over which unrecognized compensation is expected to be recognized			3 years
Research and Development [Member]
Share-based Compensation Expense [Abstract]
Share-based compensation expense	79,561	10,820	$ 131,812	73,395
Sales and Marketing [Member]
Share-based Compensation Expense [Abstract]
Share-based compensation expense	623	1,515	(1,319)	3,857
General and Administrative [Member]
Share-based Compensation Expense [Abstract]
Share-based compensation expense	$ 424,175	$ 39,427	$ 496,036	$ 81,036

Equity Incentive Plans and Wa_6

Equity Incentive Plans and Warrants, Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan [Member]	9 Months Ended
	Sep. 30, 2023 shares
Employee Stock Purchase Plan [Abstract]
Stock issued (in shares)	3,858
Common stock reserved for issuance (in shares)	394,704

Equity Incentive Plans and Wa_7

Equity Incentive Plans and Warrants, April 2023 Financing (Details) - USD ($)		1 Months Ended		9 Months Ended
	Apr. 20, 2023	Sep. 30, 2023	Apr. 30, 2023	Sep. 30, 2023	Sep. 30, 2022
Warrants [Abstract]
Issuance and sale of common stock (in shares)	1,318,000
Gross proceeds from offering	$ 3,899,813		$ 3,899,813
Transaction costs	547,764			$ 547,764	$ 0
Common stock value	1,133,480
Estimated Fair Value Assumptions [Abstract]
Net proceeds from issuance of common stock and warrants	$ 3,352,049
Cash proceeds from warrants exercised		$ 1,059,975		$ 1,059,975	$ 0
Pre-funded Warrants [Member]
Warrants [Abstract]
Warrants issued to purchase common stock (in shares)	1,878,722
Warrants exercise price (In dollars per share)	$ 0.0001
Common stock value	$ 1,615,701
Estimated Fair Value Assumptions [Abstract]
Expected term (in years)	4 years
Risk free interest rate	3.83%
Dividend yield	0%
Expected volatility	100.25%
Exercise price (in dollars per share)	$ 0.0001
Stock price (in dollars per share)	0.86
Black-Scholes value (in dollars per share)	$ 0.86
Common Warrants [Member]
Warrants [Abstract]
Warrants issued to purchase common stock (in shares)	3,196,722
Warrants term		5 years 6 months		5 years 6 months
Warrants exercise price (In dollars per share)	$ 1.095
Common stock value	$ 1,854,099
Estimated Fair Value Assumptions [Abstract]
Expected term (in years)	4 years
Risk free interest rate	3.83%
Dividend yield	0%
Expected volatility	100.25%
Exercise price (in dollars per share)	$ 1.095
Stock price (in dollars per share)	0.86
Black-Scholes value (in dollars per share)	$ 0.58
Warrants exercised (in shares)		796,722
Warrants outstanding (in shares)		2,400,000		2,400,000
Placement Agent Warrants [Member]
Warrants [Abstract]
Warrants issued to purchase common stock (in shares)	191,803
Warrants term		5 years		5 years
Warrants exercise price (In dollars per share)	$ 1.525
Estimated Fair Value Assumptions [Abstract]
Warrants exercised (in shares)		122,994
Warrants outstanding (in shares)		68,809		68,809

Net Loss per Share Attributab_3

Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Net Loss per Share Attributable to Common Stockholders [Abstract]
Net loss attributable to common stockholders, basic	$ (3,996,905)	$ (2,982,843)	$ (9,836,670)	$ (8,499,974)
Net loss attributable to common stockholders, diluted	$ (3,996,905)	$ (2,982,843)	$ (9,836,670)	$ (8,499,974)
Weighted average number of shares used in computing net loss per share attributable to common stockholders, basic (in shares)	15,093,147	11,813,610	13,369,462	11,810,289
Weighted average number of shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	15,093,147	11,813,610	13,369,462	11,810,289
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.26)	$ (0.25)	$ (0.74)	$ (0.72)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.26)	$ (0.25)	$ (0.74)	$ (0.72)
Weighted Average Number of Shares Outstanding [Abstract]
Options to purchase common stock (in shares)	2,229,271	1,071,573	2,229,271	1,071,573
Warrants to purchase common stock, in connection with April 2023 financing (in shares)	2,468,809	0	2,468,809	0
Warrants to purchase common stock (in shares)	233,460	233,460	233,460	233,460
Total potential shares (in shares)	4,931,540	1,305,033	4,931,540	1,305,033

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)		1 Months Ended		9 Months Ended
	Apr. 20, 2023	Oct. 31, 2023	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022
Issuance Sale of Common Stock [Abstract]
Cash proceeds from warrants exercised			$ 1,059,975	$ 1,059,975	$ 0
Gross cash proceeds from offering	$ 3,352,049
Common Warrants [Member]
Issuance Sale of Common Stock [Abstract]
Warrants exercised (in shares)			796,722
Subsequent Event [Member] | At-the-Market Facility [Member]
Issuance Sale of Common Stock [Abstract]
Common stock authorized value to be issued by Sales Agent		$ 16,700,000
Sale of common stock (in shares)		3,256,754
Gross cash proceeds from offering		$ 7,661,587
Subsequent Event [Member] | Common Warrants [Member]
Issuance Sale of Common Stock [Abstract]
Warrants exercised (in shares)		2,400,000
Cash proceeds from warrants exercised		$ 2,628,000